CD Expression in Prostate Cancer

描述（由申请人提供）：簇命名（CD）分子是在我们身体的各种细胞类型中差异表达的细胞表面抗原。前列腺的主要细胞类型可以通过它们的CD表达来鉴定。前列腺癌细胞的CD表型为CD 10-/CD 13-CD 24/CD 26 +/CD 38/CD 57 +/CDw 75 +/CD 107 b+，在许多检查的肿瘤中发现。除了CD 10和CD 13外，它类似于管腔细胞的CD 10 +/CD 13 +/CD 24 +/CD 26 +/CD 38 +/CD 57 +/CDw 75 +/CD 107 b+模式，而与基底细胞的CD 10-/CD 13-/CD 24-/CD 26-/CD 38 +/CD 57-/CDw 75-/CD 107 b-模式非常不同。因此，癌细胞与它们的正常对应物的不同之处在于不表达CD 10和CD 13，增加表达CD 24，以及减少或不表达CD 38。还发现了变异的癌症CD表型，例如评分为CD 10+的癌细胞。约25%的分析的原发性肿瘤含有CD 10+癌细胞。与原发性肿瘤不同，迄今为止分析的所有淋巴结转移都有CD 10+癌细胞。顺便说一下，淋巴结来源的细胞系LNCaP和异种移植物LuCaP 35都是CD 10+。因此，前列腺肿瘤可以通过其癌细胞类型的组成来表征，因此它们的行为由这些组成细胞类型控制。某些癌细胞类型的存在将指示特定的疾病过程（例如转移到淋巴结）。因此，癌症CD表型可用于将患者分为不同的预后组，并更准确地预测临床结果。虽然在癌细胞类型中存在CD分子的差异表达，但在几乎所有类型中都发现了几种CD分子，并且这些分子可以靶向细胞杀伤作为治疗播散性疾病的手段。我们建议在假定的癌前病变、原发肿瘤和转移瘤中定义前列腺细胞类型组成。这项研究对更好的前列腺癌诊断和预后有很大的潜力。将使用体外三维细胞培养系统来研究CD 10或CD 13表达缺失对前列腺上皮细胞分化的影响。CD 10和CD 13都是肽酶，可能参与生物活性信号肽的加工。它们的缺失可能导致异常的细胞分化和癌症的发展。

DESCRIPTION (provided by applicant): Cluster designation (CD) molecules are cell surface antigens differentially expressed among the various cell types of our body. The major cell types of the prostate can be identified by their CD expression. The CD phenotype for prostate cancer cells is CD10-/CD13-CD24/CD26+/CD38/CD57+/CDw75+/CD107b+, found for many tumors examined. It is like the CD10+/CD13+/CD24+/CD26+/CD38+/CD57+/CDw75+/CD107b+ pattern of luminal cells save for CD10 and CD13, and very unlike the CD10-/CD13-/CD24-/CD26-/CD38+/CD57-/CDw75-/CD107b- pattern of basal cells. Hence, cancer cells differ from their normal counterpart in the absent expression of CD10 and CD13, increased expression of CD24, and diminished or absent expression of CD38. Variant cancer CD phenotypes such as cancer cells scored CD10+ are also found. About 25% of the primary tumors analyzed contain CD10+ cancer cells. And unlike primary tumors, all lymph node metastases analyzed to date have CD10+ cancer cells. Incidentally, node-derived cell line LNCaP and xenograft LuCaP 35 are both CD10+. Prostate tumors can therefore be characterized by their composition of cancer cell types, and accordingly their behavior is governed by these constituent cell types. The presence of certain cancer cell types would indicate a particular disease course (metastasis to lymph nodes, for example). Thus, cancer CD phenotypes can be used to stratify patients into different prognostic groups and to predict clinical outcome more accurately. While there is differential expression of CD molecules among the cancer cell types several CD molecules are found in almost all types, and these molecules can be targeted for cell killing as a means to treat disseminated disease. We propose to define prostate cell type compositions in putative premalignant lesions, primary tumors and metastases. This study has great potential towards better prostate cancer diagnosis and prognosis. An in vitro three-dimensional cell culture system will be used to study the effect of absent CD10 or CD13 expression in prostate epithelial cell differentiation. CD10 and CD13 are both peptidases and are likely involved in the processing of bioactive signaling peptides. Their absence might lead to the aberrant cellular differentiation and development of cancer.